Live Breaking News & Updates on Talazoparib

Stay informed with the latest breaking news from Talazoparib on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Talazoparib and stay connected to the pulse of your community

The Role of Combination Therapy in mCRPC

Rashid K. Sayyid, MD, MSc, discusses the role of combination therapy in metastatic castrate-resistant prostate cancer.

Prostate-cancer-treatment-landscape , Combination-therapy , Prostate-cancer , Prostate-cancer-treatments , Parp-inhibitors , Metastatic-castrate-resistant-prostate-cancer , Mcrpc , Talazoparib , Enzalutamide , Olaparib , Abiraterone

#VisualAbstract: Talazoparib plus enzalutamide improves progression-free survival in metastatic prostate cancer

Click to read the study in The Lancet ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Minute-medicine-inc , Prostate-cancer , Talazoparib , Studygraphics ,

Talazoparib plus enzalutamide improves progression-free survival in metastatic prostate cancer

1. Progression-free survival was significantly higher in the talazoparib plus enzalutamide group compared to enzalutamide alone. 2. There were no treatment-related fatalities among patients in the talazoparib group. Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer is the second most common malignancy among men. Despite existing therapies, metastatic castration-resistant prostate cancer (mCRPC) remains a

Rating-level , Metastatic-castration-resistant-prostate , Between-jan , Enzalutamide , Metastatic-castration-resistant-prostate-cancer , Metastatic-castration-resistant-prostate-cancer-mcrpc- , Oncology , Prostate-cancer , Prostate-cancer-metastasis , Talazoparib , Chronic-disease

FDA Approves Talazoparib Plus Enzalutamide for HRR Gene–Altered mCRPC

The FDA has approved talazoparib (Talzenna) plus enzalutamide (Xtandi) for use in patients with homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

Prostate-cancer-working-group , Talazoparib , Enzalutamide , Mcrpc , Prostate-cancer ,

Metastatic CRPC: Advent of PARP Inhibitors

Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.

Key-updates , Metastatic-prostate-cancer-treatment , Prostate-cancer , Metastatic-castration-resistant-prostate-cancer , Castration-resistant-prostate-cancer , Mcrpc , Crpc , Parp-inhibition , Parp-inhibitors , Olaparib , Abiraterone

A New Combination Therapy Regimen Shows Promising Results For Prostate Cancer

TALAPRO-2 demonstrated that using talazoparib in combination with enzalutamide may reduce the risk of disease progression or death by 37%.

United-states , American , Neeraj-agarwal , Cancer-learning-center , Huntsman-cancer-institute , Cancer-research-at-huntsman-institute , National-cancer-institute , Presidential-endowed-chair , Cancer-research , American-society , Clinical-oncology-genitourinary-cancers-symposium , Cancer-institute